PepTC Vaccines Limited is a recently formed subsidiary of Treos Bio Limited, a privately held, clinical stage biopharma company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. Treos Bio uses proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by its diagnostic tests to respond.
At PepTC Vaccines our efforts are focused on the development of an effective, safe and potentially best-in-class vaccine against SARS-CoV-2 addressing the challenges of the heterogeneity of individuals’ immune response, the potential for structural variations in the infecting virus and the observed phenomenon of long-term immunity to coronaviruses likely stemming from T cell activity.
Based on our clinical experience with our PolyPEPI peptide immunotherapy in metastatic colorectal cancer patients and our validated in silico human model, we believe that our approach has the potential to provide a broad and long-lasting immune response, independent of gender, age or ethnicity, that will be able to protect people worldwide against COVID-19.